Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
QuintilesIMS
Chinese Patent Office
Teva
Healthtrust
Harvard Business School
Dow
Chubb
Queensland Health

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,052,987

« Back to Dashboard

Which drugs does patent 8,052,987 protect, and when does it expire?

Patent 8,052,987 protects RECLAST and is included in one NDA.

This patent has thirty-eight patent family members in twenty-eight countries.
Summary for Patent: 8,052,987
Title:Method of administering bisphosphonates
Abstract: The invention relates to bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, and to methods of treatment using bisphosphonates. These bisphosphonates are used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.
Inventor(s): Horowitz; Zebulun D. (Basking Ridge, NJ), Richardson; Peter C. (Far Hills, NJ), Trechsel; Ulrich (Luzein, CH)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:10/311,942
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,052,987

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis RECLAST zoledronic acid INJECTABLE;IV (INFUSION) 021817-001 Apr 16, 2007 AP RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,052,987

PCT Information
PCT FiledJune 18, 2001PCT Application Number:PCT/EP01/06850
PCT Publication Date:December 27, 2001PCT Publication Number: WO01/97788

International Patents Family Members for US Patent 8,052,987

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 203087 ➤ Subscribe
Poland 358224 ➤ Subscribe
New Zealand 523086 ➤ Subscribe
Norway 330459 ➤ Subscribe
Norway 20026117 ➤ Subscribe
Mexico PA02012682 ➤ Subscribe
Luxembourg 92174 ➤ Subscribe
South Korea 100864743 ➤ Subscribe
South Korea 20030015283 ➤ Subscribe
Japan 5005188 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Harvard Business School
Johnson and Johnson
US Department of Justice
Express Scripts
Citi
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot